EUCTR2007-004640-78-FR进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, 4-way crossover study of ITI-007 in subjects with sleep maintenance insomnia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Males aged 18 to 65 years, inclusive,
- •? Females aged 18 to 65 inclusive, must be of non-childbearing potential (defined as either surgically sterilized or at least 1 year post-menopausal),
- •? based on subject information, the patient has spent at least 6.5 hours and not more than 9.0 hours in bed, each night, with no more than 2 hour variability in 5 out of 7 nights over the preceding 2 weeks,
- •? subjects must be experiencing at least one hour of wakefulness after sleep onset at least 3 nights per week over the preceding month with a subjective total sleep time of 6.5 hours or less,
- •? subjects must report an impact associated with sleep maintenance insomnia, as measured by a score of at least at 2 or higher on at least one of the Questions # 2, 3, 4, or 5 of the Insomnia Severity Index (with the whole scale being administered to define baseline insomnia),
- •? subjects must report a usual bedtime of between 9 pm and midnight,
- •? subjects must have a body-mass index (BMI) between >19 and <34 kg/m2,
- •? subjects must be able to give informed consent,
- •? screening polysomnography criteria: PSG WASO > 45 min, PSG TST between 4 and 7 hours, inclusive, based on screening/baseline PSG criteria,
- •? subjects must be affiliated with, or beneficiary of, a French social security system.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? likely allergy or sensitivity to ITI-007 based on known allergies to drugs of the same class, or which in the opinion of the Investigator, suggests an increased potential for an adverse hypersensitivity to ITI-007,
- •? females who are lactating/breast feeding or who are pregnant, or of child bearing potential,
- •? history of drug or alcohol dependence within 12 months of study start or a positive screening test for alcohol (breathalyzer) or positive urine drug screen,
- •? history or current diagnosis of primary hypersomnia, restless leg syndrome, periodic leg movements with arousals (PLMA), narcolepsy, rapid eye movement (REM) motor dysfunction disorder, circadian rhythm sleep disorder, breathing related sleep disorder, or parasomnias,
- •? history or current diagnosis of stroke, head trauma, seizure disorder, or other neurological disorder considered clinically relevant,
- •? subjects with current diagnosis and treatment of Axis I psychiatric disorder (for example, schizophrenia, mood disorders, anxiety disorders, eating disorders, etc) other than insomnia,
- •? subjects with acute or chronic pain resulting in insomnia,
- •? shift work and/or recent significant travel across three or more time zones within the prior 2 weeks,
- •? napping 3 or more times during the day or self reported napping of >45 min per day,
- •? evidence of any clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety,
- •? a positive test for hepatitis B (HBs antigens),C (HCV antibodies), or HIV,
- •? consumption of xanthine –containing beverages (e.g., tea, coffee, or caffeine containing soft drinks) comprising usually more than 5 cups/glasses or > 1 liter per day,
- •? clinically significant and abnormal ECG (including prolonged QTcB > 450 msec male and > 470 msec female),
- •? any clinically significant abnormality in laboratory examinations, or vital signs performed at screening,
- •? smoking more than 10 cigarettes (or equivalent) per day,
- •? use of any of the following medications within the prior two weeks of screening: benzodiazepines, zolpidem, (es)zopiclone, modafinil, gabapentin, gaboxadol, mianserin, mirtazepine, cyproheptadine, ramelteon, herbal preparations (e.g., St. John’s Wort, valerian root, and kava kava), over the counter sleep preparations (e.g., antihistamines, decongestants, and anticholinergics), or melatonin,
- •? use of any investigational drug within 90 days prior to study entry or participation in a previous study with ITI-007,
- •? history of blood donation (> = 500 ml) within 90 days prior to study entry,
- •? PSG TST < 4 hours or > 7 hours, PSG WASO < = 45 minutes each night, Apnea-hypopnea index (AHI) > 10 or periodic leg movements with arousals index (PLMAI) > 15, based on screening/baseline PSG criteria,
- •? any subject judged by the principal investigator (PI) to be inappropriate for the study,
- •? any subject being in the exclusion related to participation in investigational drug studies according to the French National File for Healthy Subjects (total annual amount higher than 4500 Euros).
研究者
相似试验
已完成
不适用
A randomized, double-blind, placebo-controlled, 4-period, two part cross-over study to evaluate the potential interaction effect between 4 mg/kg and 16 mg/kg sugammadex and enoxaparin or unfractionated heparin on anticoagulation activity in young healthy male volunteerscoagulationthrombus10014523NL-OMON36201Schering-Plough80
已完成
不适用
A randomized, double-blind, placebo-controlled, 4-period cross-over drug-drug interaction study to evaluate the effect of sugammadex and aspirin on platelet aggregation and coagulation parameters in young healthy male volunteerscoagulationplatelet aggregation1003553410014523NL-OMON34161Schering-Plough36
已完成
2 期
Soluble fibre for asthma controlAsthmaACTRN12618001362280niversity of Newcastle40
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, 4-way crossover clinical trial to assess the efficacy, safety, tolerability and pharmacokinetics of single doses of LAS100977 administered by inhalation to stable asthma patientsAdult male subjects, aged 18 to 70 years, clinically diagnosed of persistent asthma (according to GINA guidelines 2007 update) for at least 6 months before screening, but who are otherwise in good general physical condition.EUCTR2008-004756-69-DEaboratorios Almirall, S.A.
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis.Seasonal Allergic RhinitisMedDRA version: 9.1Level: LLTClassification code 10039776Term: Seasonal allergic rhinitisEUCTR2008-004092-22-DEGlaxSmithKline Research & Development Limited